VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

Peter Schmid, Javier Cortés, Rebecca Alexandra Dent et al. · Annals of Oncology · 2021

Cited by 135 works. doi:10.1016/j.annonc.2021.06.014 Open-access PDF

Authors

References